Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Glimcoza vs Twymeeg (Imeglimin) in Healthy Subjects
NCT07127094Phase 1Completed
- Start
- Mar 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of imeglimin in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoints: Area Under the Curve from time zero to 72 hours, Area Under the Curve from time zero to infinity at 72 hours and 1 more. Started Mar 2025; status: completed.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07127094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07127094.